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without giving up radical treatment for those who need it. 
In later cases, the definitive treatment should be curative. 
There are several groups of criteria defining low risk pros-
tate cancer eligible for AS (e.g. clinically confined prostate 
cancer (p T1-T2), Gleason score ≤7, PSA <15 – 20 ng/ml)4,5. 
In our study we tested Epstein biopsy criteria for predict-
ing unfavorable final pathology and biochemical relapse 
in the group of low risk prostate cancer patients, who were 
eligible for active surveillance but where treated with 
radical prostatectomy.
Material and Methods
From January 2003 until January 2008, in our institu-
tion 586 patients were subjected to retropubic radical pros-
tatectomy. Among them, 106 patients were eligible for 
active surveillance under preoperative biopsy criteria de-
Introduction
Insignificant prostate cancer is defined as a biologi-
cally indolent disease that poses no threat to the patient s´ 
life1. Due to wide use of prostate specific antigen (PSA), 
stage and grade migration towards low stage, low volume 
disease is noted. Fear of over diagnosis and overtreatment 
of indolent prostate cancer raised the question of optimal 
treatment of early prostate cancer. Active surveillance is 
a legitimate option for treatment of low risk, localized 
prostate cancer2. It includes an active decision not to treat 
patients immediately, but to follow them with a surveil-
lance protocol and to treat them at predefined thresholds 
that classify progression of the disease (short PSA dou-
bling time and deteriorating histopathological factors on 
repeat biopsy) while the disease is still curable3. The aim 
of active surveillance is to reduce the overtreatment in 
patients with organ confined low risk prostate cancer, 
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A B S T R A C T
Only few reports validated contemporary Epstein criteria for insignificant prostate cancer, and only one being from 
Europe. Patients with insignificant prostate cancer should be offered active surveillance and spared radical treatment. 
In our study we tested Epstein biopsy criteria for predicting unfavorable final pathology and biochemical relapse in low 
risk prostate cancer patients, who were eligible for active surveillance but where treated with radical prostatectomy. Be-
tween January 2003 and January 2008, 586 patients were subjected to radical prostatectomy in our institution. Among 
them, 106 where eligible for active surveillance according to Epstein biopsy criteria for insignificant prostate cancer. We 
analyzed the presence of adverse pathological findings in the final pathohistological specimen after radical prostatectomy 
which excludes low risk disease. Adverse pathohistological findings were noted in 41 (38.6%) patients, who could have 
been offered active surveillance. During the follow up of 48 (12 – 72) months, biochemical relapse was noted in 6 (5.6%) 
patients. Although active surveillance is becoming more popular because of the long natural course of prostate cancer and 
fear of overtreatment of patients with indolent course of disease, both doctors and patients must be aware of potentially 
significant disease in this group and limitations of current preoperative criteria defining low risk patients.
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found in 6.6%, 8.4% and 1.8% patients, respectively. Glea-
son score 7 was noted in 39 patients in the final pathohis-
tological report, and Gleason score 8 – 10 in none. Total, 
adverse pathohistological finding was noted in 41 patients, 
which was 38.6% of all patients that could be offered active 
surveillance. During the follow – up of 48 (12 – 72) months 
biochemical relapse was noted in 6 patients.
Discussion
Prostate cancer is accounted for 14% of new male can-
cers in Croatia in 20066. Cancer – specific 10 – year sur-
vival rates for stage T1a patients is 96% and 94%, for well 
and good differentiated tumours7. The metastasis – free 
10 – year survival rate was 92% for patients with well, but 
78% for those with good differentiated tumours7. The 15 
year risk of dying from prostate cancer in relation to Glea-
son score at diagnosis in patients with localized disease 
aged 55 – 74 years is, for Gleason score 5, 6 and 7, 6 – 11%, 
18-30% and 42 – 70%, respectively8,9. In our study, we 
tried to reevaluate current criteria for enrolling presum-
ably low – risk prostate cancer patients to active surveil-
lance. We used the most stringent criteria according to the 
literature8,9. In our group of patients with presumably low 
– risk prostate cancer according to established criteria, 
38.6% had adverse pathohistological findings, and 5.6% 
had biochemical relapses after the operation they were 
subjected to.
Conclusion
Although active surveillance is becoming more popular 
because of the long natural course of prostate cancer and 
fear of overtreatment patients with indolent course of dis-
ease, both doctors and patients must be aware of poten-
tially significant disease in this group and limitations of 
current preoperative criteria defining low – risk patients.
fined by Epstein. These criteria imply clinical stage T1c 
– T2, PSA density <0.15 ng/ml/ml, biopsy Gleason score 
≤3+3, ≤2 positive biopsy cores, ≤50% involvement by can-
cer in any single core. Data were obtained from a prospec-
tively maintained database of patients who were biopsied 
and operated in our institution. Both preoperative and 
postoperative serum PSA were obtained in our institution 
using the same kit. The biopsy and radical prostatectomy 
specimens were processed using standard fixation proto-
col and were evaluated by two uropathologists. PSA den-
sity was calculated using preoperative PSA divided by 
measured volume of the prostate in the radical prostatec-
tomy specimen since preoperative transrectal ultrasound 
volume was not available for all patients. We analyzed 
presence of the adverse pathological findings in the final 
pathohistological specimen after radical prostatectomy 
which exclude low risk disease: presence of extracapsular 
spread of the disease (ECE), positive surgical margins 
(+SM), affectedness of the seminal vesicle (+ SV), positive 
lymph nodes (PLN) and Gleason score 7 – 10.
Statistical analysis
Data were described as frequency tables. Analysis was 
performed using StatView 5.0 (SAS Institute Inc, Cary, 
NC, USA). Statistical significance was set at p<0.05%.
Results
From 586 patients treated with radical prostatectomy 
in the analyzed period, 106 belonged to the low – risk 
group of patients for the above preoperative criteria and 
could be subjected to active surveillance. Mean age was 
65 (46 – 7) year, mean PSA was 7.1 (3.0 – 10.0) ng/mL, 
mean biopsy Gleason score was 5.8 (4 – 6), mean number 
of biopsy core was 8 (6 – 12), mean percent of tumor in core 
was 18 (5 – 50)%. Among them ECE, + SM, SVI were 
R E F E R E N C E S
1. KLEIN EA, Cancer, 101 (2004) 1923. DOI: 10.1002/cncr.20584. – 2. 
BASTIAN PJ, MANGOLD LA, EPSTEIN JI, PARTIN AW, Cancer, 101 
(2004) 2001. DOI: 10.1002/cncr.20586. – 3. KLOTZ L, JCO, 32 (2005) 
8165. DOI: 10.1200/JCO.2005.03.3134. – 4. HEIDENREICH A, AUS G, 
BOLLA M, JONIAU S, MATVEEV V, SCHMID HP, ZATTONI F, Eur 
Urol, 53 (2008) 68. DOI: 10.1016/j.eururo.2007.09.002. – 5. ADOLFSSON 
J, BJU Int, 102 (2008) 10. DOI: 10.1111/j.1464-410X.2008.07585.x. – 6. 
Latest data Of Cancer monitoring with a registry, Croatian Institute of 
Public Health, accessed 29.07.2013, Available from: URL: http://www.
hzjz.hr/rak/novo.htm. – 7. CHODAK GW, THISTED RA, GERBER GS, 
JOHANSSON JE, ADOLFSSON J, JONES GW, CHISHOLM GD, MOS-
KOVITZ B, LIVNE PM, WARNER J, N Engl J Med, 330 (1994) 220. DOI: 
10.1056/NEJM199401273300403. – 8. ALBERTSEN PC, HENLEY JA, 
GLEASON DF, BARRY MJ, JAMA, 280 (1998) 975. DOI: 10.1001/
jama.280.11.975. – 9. ALBERTSEN PC, HENLEY JA, MURPHY SM, J 
Urol, 162 (1999) 439. DOI: 10.1016/S0022-5347(05)68580-1.
I. Pezelj
University of Zagreb, »Sestre milosrdnice« University Hospital Center, »Ljudevit Jurak« University Department of 
Pathology, Vinogradska cesta 29, 10000 Zagreb, Croatia 
e-mail: pezelj.ivan@gmail.com
711
I. Tomašković: Validation of Epstein Biopsy Criteria in Croatia, Coll. Antropol. 39 (2015) 3: 709–711
PATOHISTOLOŠKI NALAZI BOLESNIKA S RAKOM PROSTATE LIJEČENIH RADIKALNOM  
PROSTATEKTOMIJOM KOJI SU BILI PODOBNI ZA AKTIVNI NADZOR
S A Ž E T A K
Samo je nekoliko radova koji potvrđuju Epsteinove kriterije za karcinome prostate niskog rizika od kojih je samo 
jedan iz Europe. Aktivni nadzor je legitimna opcija kod lokaliziranog karcinoma prostate niskog rizika. U našem 
istraživanju testirali smo u skupini bolesnika niskog rizika, koja je liječena radikalnom prostatektomijom, najstrože 
preoperativne kriterije za aktivni nadzor. Od siječnja 2003. do siječnja 2008. retropubičnoj radikalnoj prostatektomiji 
podvrgnuto je 586 bolesnika od kojih je 106 bilo podobno za aktivni nadzor prema kombiniranim preoperativnim kriteri-
jima koje su definirali van den Bergh i Carter. Analizirali smo prisutnost nepovoljnih patoloških nalaza na konačnom 
patohistološkom preparatu nakon prostatektomije koji isključuju bolest niskog rizika. Ukupno, nepovoljan patohistološki 
nalaz bio je prisutan u 41 bolesnika, što je 38,6% bolesnika kojima je mogao biti ponuđen i aktivni nadzor. Tijekom 
perioda praćenja od 48 (12-72) mjeseci biokemijski relaps zabilježen je u 6 bolesnika. Premda aktivni nadzor postaje 
popularan zbog dugog prirodnog tijeka raka prostate i straha od pretjeranog liječenja bolesnika sa indolentnim tijekom 
bolesti i liječnici i bolesnici moraju biti svjesni potencijalno signifikatne bolesti u ovoj skupini i ograničenja sadašnjih 
preoperativnih kriterija koji definiraju bolesnike niskog rizika.
